Why So Few? | GenomeWeb

Why So Few?

Some clinical cancer trials don't attract the wanted number of participants. And there are a number of reasons why, such as competing trials, conditions with low annual incidence, and whether they focus on older treatments rather than newer ones, according to researchers from the University of Washington and the Fred Hutchinson Cancer Research Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.